相关实验视频
Updated: May 29, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
270
对肥胖管理的尖端方法:最新的药理选择
Sarah H Schmitz1, Katherine H Saunders1, Louis J Aronne1
1Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, NY 10021, USA.
Endocrinology and metabolism clinics of North America
|February 7, 2025
概括
有效的肥胖治疗结合了饮食,运动和行为改变. 本综述详细介绍了FDA批准的七种抗肥胖药物,这些药物对于长期治疗慢性疾病至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 肥胖是一种复杂的慢性疾病,需要多方面的管理策略.
- 目前的治疗模式强调生活方式干预与药物治疗一起.
研究的目的:
- 为提供FDA批准的抗肥胖药物的全面概述.
- 总结支持药物批准的关键临床试验数据.
- 审查每个药物的基本处方信息.
主要方法:
- 对FDA批准的抗肥胖药物3期临床试验数据的系统审查.
- 收集有关适应症,机制,剂量和安全性资料的信息.
主要成果:
- 总结了七种抗肥胖药物的基准试验的详细疗效和安全数据.
- 审查了包括禁忌和药物相互作用在内的关键处方信息.
结论:
- 目前有七种抗肥胖药物,每种药物都有特定的适应症和特征.
- 这些药物治疗是作为慢性疾病的肥胖症长期管理的组成部分.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
183
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
183
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Diabetes: Management and Pharmacotherapy
232
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
232
Inflammatory Bowel Disease IV: Pharmacological Management
99
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
99
Antidepressant Drugs: Overview
351
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
351
Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37

